Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

along with its partner Moffitt Cancer Center ("Moffitt"), has received approval for an amendment to the protocol governing its ongoing clinical trial using CAR-T therapy for the treatment of ...

In this video interview, Dominique Demolle, CEO of Cognivia, highlights how patient non-adherence could increase trial ...

Oncology studies present unique challenges when it comes to participant treatment, resupply, and study management.

A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio, Senior Trial Design Lead, ...

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency ...

Now such calls to make clinical trial data transparent – along with openly accessible protocols, papers, and summary results – are really burgeoning, and it’s easy to lose the plot.

Some people may remain ill after COVID infection because the virus still lurks in their bodies. The looming question now is: ...